FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 355:385-392 July 27, 2006 Number 4 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text PowerPoint Slide Set Supplementary Material Purchase this article Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

This Journal feature begins with a case vignette highlighting a common clinical problem. Evidence supporting various strategies is then presented, followed by a review of formal guidelines, when they exist. The article ends with the authors' clinical recommendations.

A 70-year-old woman with a long-standing history of hypertension comes for follow-up. Her medications include atenolol (100 mg daily), hydrochlorothiazide (12.5 mg daily), lisinopril (40 mg daily), and ibuprofen (400 mg twice daily for osteoarthritis). She does not smoke or drink alcohol. Her body-mass index (the weight in kilograms divided by the square of the height in meters) is 32. Her systolic . . . [Full Text of this Article]

The Clinical Problem

Strategies and Evidence

Diagnosis

            Adherence to Treatment

            Interfering or Exogenous Substances

            Evaluation of Secondary Hypertension

Treatment

Guidelines

Areas of Uncertainty

Summary and Recommendations

Source Information

From the Section of Cardiovascular Medicine and the Cardiovascular Disease Prevention Center, Department of Internal Medicine, Yale University School of Medicine, New Haven, Conn.

Address reprint requests to Dr. Moser at the Section of Cardiovascular Medicine, Yale University School of Medicine, Box 208017, 333 Cedar St., New Haven, CT 06520.

Related Letters:

Resistant or Difficult-to-Control Hypertension
Chandran P., Moser M., Setaro J.
Extract | Full Text | PDF  
N Engl J Med 2006; 355:1934, Nov 2, 2006. Correspondence

This article has been cited by other articles:

• On behalf of the Canadian Hypertension Education P, (2009). 2009 Canadian Hypertension Education Program recommendations: An annual update. cfp 55: 697-700 [Full Text]  
• Jennings, J. R., Muldoon, M. F., Whyte, E. M., Scanlon, J., Price, J., Meltzer, C. C. (2008). Brain Imaging Findings Predict Blood Pressure Response to Pharmacological Treatment. Hypertension 52: 1113-1119 [Abstract] [Full Text]  
• Sarafidis, P. A., Bakris, G. L. (2008). Resistant Hypertension An Overview of Evaluation and Treatment.. J Am Coll Cardiol 52: 1749-1757 [Abstract] [Full Text]  
• Epstein, B. J (2008). Efficacy and Safety of Darusentan: A Novel Endothelin Receptor Antagonist. The Annals of Pharmacotherapy 42: 1060-1069 [Abstract] [Full Text]  
• Chandran, P., Moser, M., Setaro, J. (2006). Resistant or Difficult-to-Control Hypertension. NEJM 355: 1934-1934 [Full Text]